Positive results with Endocine™ and a vaccine candidate against COVID-19
STOCKHOLM, Sept. 23, 2021 /PRNewswire/ -- The first preclinical study, where the adjuvant technology Endocine™ has been evaluated with a vaccine candidate against COVID-19, shows positive results.
In May 2021, Eurocine Vaccine signed an evaluation agreement with an innovative North American company with the ambition to evaluate Endocine™ along with their vaccine candidate against COVID-19.
The first study in a mouse model indicates positive results with our adjuvant Endocine™, where antibodies of both type IgA and IgG could be detected, as well as T cell immunity.
The North American company now intends to proceed with additional studies where Eurocine Vaccines will deliver Endocine™ and assist with knowledge and experience within the area.
Read more about our adjuvant:
https://www.eurocine-vaccines.com/the-portfolio/
CONTACT:
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
[email protected]
+46 70 634 0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Positive results with Endocineâ„¢ and a vaccine candidate against COVID-19 |
SOURCE Eurocine Vaccines
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article